NCT02515175 - Evaluating New Formulation of Therapeutic HSV-2 Vaccine | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

May 25, 2017

Conditions

Genital Herpes Simplex Type 2

Interventions

BIOLOGICAL

Matrix-M2

Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

BIOLOGICAL

GEN-003

HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

DRUG

Placebo

0.9% Normal Saline

Trial Locations (8)

27599

University of North Carolina - Chapel Hill, Chapel Hill

35294

University of Alabama-Birmingham, Birmingham

45229

Cincinnati Childrens Hospital, Cincinnati

78745

Tekton Research, Austin

92108

Medical Center for Clinical Research, San Diego

94115

Quest Clinical Research, San Francisco

98104

University of Washington, Seattle

02215

The Fenway Institute, Boston